ADRs derived from clinical studies and post-marketing surveillance with Ciproxin (oral, intravenous and sequential therapy) sorted by categories of frequency are listed as follows. The frequency analysis takes into account data from both oral and intravenous administration of ciprofloxacin. (See Table 11.)
![](https://mpfshstrg.blob.core.windows.net/mpf-uat-common-resources/Images/monograph/table.gif)
The following undesirable effects have a higher frequency category in the subgroups of patients receiving intravenous or sequential (intravenous to oral) treatment: See Table 12.
![](https://mpfshstrg.blob.core.windows.net/mpf-uat-common-resources/Images/monograph/table.gif)
Paediatric population: The incidence of arthropathy (arthralgia, arthritis), mentioned previously, is referring to data collected in studies with adults. In children, arthropathy is reported to occur commonly (see Precautions).
Reporting of suspected adverse reactions: Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.
View ADR Monitoring Form